I-O Drugs: Key to the Cancer Moonshot?



Please complete the form below to view the webinar recording. 

Name *
Communication Preferences
Thank you for your interest in Context Matters. You will receive future communications. To opt-out, check the box below.

Checkpoint inhibitor immuno-oncology (I-O) treatments, widely considered as one the most promising breakthroughs in drug development, are a focus of the Cancer Moonshot initiative. But are these new therapies getting reimbursed and what are the challenges they face in gaining market access?

This webinar takes a data-driven look at the key challenges facing I-O drugs including:

  • Cost and value
  • Interpretation of clinical efficacy evidence
  • Restrictions issued by HTA agencies